Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies

Alessandra Porzia, Stefania Lanzardo, Arianna Citti, Federica Cavallo, Guido Forni, Angela Santoni, Ricciarda Galandrini, Rossella Paolini

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

By studying BALB/c mice deficient in immune components, we show that the protective immunity to rat ErbB2+ tumors rests on the Ab response elicited by the electroporation of a DNA vaccine encoding the extracellular and transmembrane domains of rat ErbB2. In vivo, the adoptive transfer of vaccine-elicited anti-rat ErbB2 Abs protected against a challenge of rat ErbB2+ carcinoma cells (TUBO cells). In vitro, such Abs inhibited TUBO cell growth by impairing cell cycle progression and inducing apoptosis. To correlate intrinsic mechanisms of Ab action with their tumor-inhibitory potential, first we showed that TUBO cells constitutively express phosphorylated transgenic ErbB2/autochthonous ErbB3 heterodimers and exhibit a basal level of Akt phosphorylation, suggesting a constitutive activation of the PI3K/Akt pathway. Treatment with anti-ErbB2 Abs caused a drastic reduction in the basal level of Akt phosphorylation in the absence of an impairment of PI3K enzymatic activity. Notably, the same Ab treatment induced an increase in PTEN phosphatase activity that correlated with a reduced PTEN phosphorylation. In conclusion, vaccine-induced anti-ErbB2 Abs directly affected the transformed phenotype of rat ErbB2+ tumors by impairing ErbB2-mediated PI3K/Akt signaling.

Original languageEnglish
Pages (from-to)4170-4177
Number of pages8
JournalJournal of Immunology
Volume184
Issue number8
DOIs
Publication statusPublished - Apr 15 2010

Fingerprint

DNA Vaccines
Phosphatidylinositol 3-Kinases
Anti-Idiotypic Antibodies
Phosphorylation
Vaccines
PTEN Phosphohydrolase
Neoplasms
Electroporation
Adoptive Transfer
Immunity
Cell Cycle
Apoptosis
Carcinoma
Phenotype
Therapeutics
Growth

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)

Cite this

Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies. / Porzia, Alessandra; Lanzardo, Stefania; Citti, Arianna; Cavallo, Federica; Forni, Guido; Santoni, Angela; Galandrini, Ricciarda; Paolini, Rossella.

In: Journal of Immunology, Vol. 184, No. 8, 15.04.2010, p. 4170-4177.

Research output: Contribution to journalArticle

Porzia, A, Lanzardo, S, Citti, A, Cavallo, F, Forni, G, Santoni, A, Galandrini, R & Paolini, R 2010, 'Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies', Journal of Immunology, vol. 184, no. 8, pp. 4170-4177. https://doi.org/10.4049/jimmunol.0903375
Porzia, Alessandra ; Lanzardo, Stefania ; Citti, Arianna ; Cavallo, Federica ; Forni, Guido ; Santoni, Angela ; Galandrini, Ricciarda ; Paolini, Rossella. / Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies. In: Journal of Immunology. 2010 ; Vol. 184, No. 8. pp. 4170-4177.
@article{106bf0195e624d05b407fda9d083c52c,
title = "Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies",
abstract = "By studying BALB/c mice deficient in immune components, we show that the protective immunity to rat ErbB2+ tumors rests on the Ab response elicited by the electroporation of a DNA vaccine encoding the extracellular and transmembrane domains of rat ErbB2. In vivo, the adoptive transfer of vaccine-elicited anti-rat ErbB2 Abs protected against a challenge of rat ErbB2+ carcinoma cells (TUBO cells). In vitro, such Abs inhibited TUBO cell growth by impairing cell cycle progression and inducing apoptosis. To correlate intrinsic mechanisms of Ab action with their tumor-inhibitory potential, first we showed that TUBO cells constitutively express phosphorylated transgenic ErbB2/autochthonous ErbB3 heterodimers and exhibit a basal level of Akt phosphorylation, suggesting a constitutive activation of the PI3K/Akt pathway. Treatment with anti-ErbB2 Abs caused a drastic reduction in the basal level of Akt phosphorylation in the absence of an impairment of PI3K enzymatic activity. Notably, the same Ab treatment induced an increase in PTEN phosphatase activity that correlated with a reduced PTEN phosphorylation. In conclusion, vaccine-induced anti-ErbB2 Abs directly affected the transformed phenotype of rat ErbB2+ tumors by impairing ErbB2-mediated PI3K/Akt signaling.",
author = "Alessandra Porzia and Stefania Lanzardo and Arianna Citti and Federica Cavallo and Guido Forni and Angela Santoni and Ricciarda Galandrini and Rossella Paolini",
year = "2010",
month = "4",
day = "15",
doi = "10.4049/jimmunol.0903375",
language = "English",
volume = "184",
pages = "4170--4177",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "8",

}

TY - JOUR

T1 - Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies

AU - Porzia, Alessandra

AU - Lanzardo, Stefania

AU - Citti, Arianna

AU - Cavallo, Federica

AU - Forni, Guido

AU - Santoni, Angela

AU - Galandrini, Ricciarda

AU - Paolini, Rossella

PY - 2010/4/15

Y1 - 2010/4/15

N2 - By studying BALB/c mice deficient in immune components, we show that the protective immunity to rat ErbB2+ tumors rests on the Ab response elicited by the electroporation of a DNA vaccine encoding the extracellular and transmembrane domains of rat ErbB2. In vivo, the adoptive transfer of vaccine-elicited anti-rat ErbB2 Abs protected against a challenge of rat ErbB2+ carcinoma cells (TUBO cells). In vitro, such Abs inhibited TUBO cell growth by impairing cell cycle progression and inducing apoptosis. To correlate intrinsic mechanisms of Ab action with their tumor-inhibitory potential, first we showed that TUBO cells constitutively express phosphorylated transgenic ErbB2/autochthonous ErbB3 heterodimers and exhibit a basal level of Akt phosphorylation, suggesting a constitutive activation of the PI3K/Akt pathway. Treatment with anti-ErbB2 Abs caused a drastic reduction in the basal level of Akt phosphorylation in the absence of an impairment of PI3K enzymatic activity. Notably, the same Ab treatment induced an increase in PTEN phosphatase activity that correlated with a reduced PTEN phosphorylation. In conclusion, vaccine-induced anti-ErbB2 Abs directly affected the transformed phenotype of rat ErbB2+ tumors by impairing ErbB2-mediated PI3K/Akt signaling.

AB - By studying BALB/c mice deficient in immune components, we show that the protective immunity to rat ErbB2+ tumors rests on the Ab response elicited by the electroporation of a DNA vaccine encoding the extracellular and transmembrane domains of rat ErbB2. In vivo, the adoptive transfer of vaccine-elicited anti-rat ErbB2 Abs protected against a challenge of rat ErbB2+ carcinoma cells (TUBO cells). In vitro, such Abs inhibited TUBO cell growth by impairing cell cycle progression and inducing apoptosis. To correlate intrinsic mechanisms of Ab action with their tumor-inhibitory potential, first we showed that TUBO cells constitutively express phosphorylated transgenic ErbB2/autochthonous ErbB3 heterodimers and exhibit a basal level of Akt phosphorylation, suggesting a constitutive activation of the PI3K/Akt pathway. Treatment with anti-ErbB2 Abs caused a drastic reduction in the basal level of Akt phosphorylation in the absence of an impairment of PI3K enzymatic activity. Notably, the same Ab treatment induced an increase in PTEN phosphatase activity that correlated with a reduced PTEN phosphorylation. In conclusion, vaccine-induced anti-ErbB2 Abs directly affected the transformed phenotype of rat ErbB2+ tumors by impairing ErbB2-mediated PI3K/Akt signaling.

UR - http://www.scopus.com/inward/record.url?scp=77952785340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952785340&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.0903375

DO - 10.4049/jimmunol.0903375

M3 - Article

VL - 184

SP - 4170

EP - 4177

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 8

ER -